no title
Published under Open Access CC-BY-NC-BD 4.0. https://creativecommons.org/licenses/by-nc-nd/4.0/..
This review highlights key aspects of treating chronic obstructive pulmonary disease (COPD) exacerbation, focusing on the optimisation of systemic corticosteroid and antibiotic use through personalised treatment using biomarkers. Eosinophil-guided therapy reduces corticosteroid usage which might reduce side effects, while procalcitonin-guided therapy contributes to reduced antibiotic consumption. These approaches, documented through well-conducted randomized controlled trials, suggest the possibility of enhancing COPD exacerbation management, reducing potential side effects, and addressing concerns related to antibiotic resistance.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:186 |
|---|---|
| Enthalten in: |
Ugeskrift for laeger - 186(2024), 14 vom: 01. Apr. |
| Sprache: |
Dänisch |
|---|
| Weiterer Titel: |
Individualised treatment of COPD exacerbations using biomarkers |
|---|
| Beteiligte Personen: |
Sivapalan, Pradeesh [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Adrenal Cortex Hormones |
|---|
| Anmerkungen: |
Date Completed 15.04.2024 Date Revised 15.04.2024 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.61409/V09230560 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM370960254 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM370960254 | ||
| 003 | DE-627 | ||
| 005 | 20240415233835.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240412s2024 xx |||||o 00| ||dan c | ||
| 024 | 7 | |a 10.61409/V09230560 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1376.xml |
| 035 | |a (DE-627)NLM370960254 | ||
| 035 | |a (NLM)38606705 | ||
| 035 | |a (PII)V09230560 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a dan | ||
| 100 | 1 | |a Sivapalan, Pradeesh |e verfasserin |4 aut | |
| 246 | 3 | 3 | |a Individualised treatment of COPD exacerbations using biomarkers |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 15.04.2024 | ||
| 500 | |a Date Revised 15.04.2024 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Published under Open Access CC-BY-NC-BD 4.0. https://creativecommons.org/licenses/by-nc-nd/4.0/. | ||
| 520 | |a This review highlights key aspects of treating chronic obstructive pulmonary disease (COPD) exacerbation, focusing on the optimisation of systemic corticosteroid and antibiotic use through personalised treatment using biomarkers. Eosinophil-guided therapy reduces corticosteroid usage which might reduce side effects, while procalcitonin-guided therapy contributes to reduced antibiotic consumption. These approaches, documented through well-conducted randomized controlled trials, suggest the possibility of enhancing COPD exacerbation management, reducing potential side effects, and addressing concerns related to antibiotic resistance | ||
| 650 | 4 | |a Review | |
| 650 | 4 | |a English Abstract | |
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Anti-Bacterial Agents |2 NLM | |
| 650 | 7 | |a Glucocorticoids |2 NLM | |
| 650 | 7 | |a Adrenal Cortex Hormones |2 NLM | |
| 650 | 7 | |a Biomarkers |2 NLM | |
| 700 | 1 | |a Eklöf, Josefin |e verfasserin |4 aut | |
| 700 | 1 | |a Bonnesen, Barbara |e verfasserin |4 aut | |
| 700 | 1 | |a Tønnesen, Louise |e verfasserin |4 aut | |
| 700 | 1 | |a Wilcke, Torgny |e verfasserin |4 aut | |
| 700 | 1 | |a Jensen, Jens-Ulrik Stæhr |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Ugeskrift for laeger |d 1945 |g 186(2024), 14 vom: 01. Apr. |w (DE-627)NLM000011185 |x 1603-6824 |7 nnns |
| 773 | 1 | 8 | |g volume:186 |g year:2024 |g number:14 |g day:01 |g month:04 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.61409/V09230560 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 186 |j 2024 |e 14 |b 01 |c 04 | ||